{
    "name": "dextroamphetamine transdermal",
    "comment": "Rx",
    "other_names": [
        "Xelstrym"
    ],
    "classes": [
        "Stimulants",
        "ADHD Agents"
    ],
    "source": "https://reference.medscape.com/drug/xelstrym-dextroamphetamine-transdermal-4000218",
    "pregnancy": {
        "common": [
            "Available data from published epidemiologic studies and postmarketing reports on amphetamine use in pregnant females have not identified a drug-associated risk of major birth defects and miscarriage "
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "Adverse pregnancy outcomes, including premature delivery and low birth weight, have been seen in infants born to mothers taking amphetamines during pregnancy",
                    "Monitor infants born to mothers taking amphetamines for symptoms of withdrawal such as feeding difficulties, irritability, agitation, and excessive drowsiness"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "In a pre- and postnatal development study, amphetamine (d- to l- ratio of 3:1) administered orally to pregnant rats during gestation and lactation caused a decrease in pup survival and a decrease in pup body weight that correlated with a delay in developmental landmarks at clinically relevant doses of amphetamine",
                    "In addition, adverse effects on reproductive performance were observed in pups whose treated mothers ",
                    "Long-term neurochemical and behavioral effects have also been reported in animal developmental studies using clinically relevant doses of amphetamine "
                ]
            },
            {
                "type": "Pregnancy exposure registry",
                "description": [
                    "Monitor pregnancy outcomes in females exposed to ADHD medications during pregnancy",
                    "Register by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or visiting online at "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no reports of adverse effects on breastfed infants",
            "Long-term neurodevelopmental effects on infants from amphetamine exposure are unknown",
            "Large doses of amphetamine may interfere with milk production, especially in women whose lactation is not well established",
            "Breastfeeding is not recommended during treatment"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Abuse and dependence",
                    "description": [
                        "CNS psychiatrics#stimulants, including dextroamphetamine transdermal, other amphetamine-containing products, and methylphenidate, have high potential for abuse and dependence",
                        "Assess risk of abuse before prescribing and monitor for signs of abuse and dependence during treatment"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to amphetamine products or other components of transdermal system; anaphylactic reactions, Stevens-Johnson syndrome, angioedema, and urticaria have been observed in postmarketing reports",
                "During or within 14 days following MAOI administration (hypertensive crises may result)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Has high potential for abuse and dependence",
                "CNS psychiatrics#stimulants may increase BP and HR; monitor for potential tachycardia and hypertension",
                "Stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs and symptoms usually improve after reducing the dose or discontinuing therapy; careful observation for digital changes is necessary during treatment; further clinical evaluation (eg, rheumatology referral) may be appropriate for certain patients",
                "Advise patients to avoid exposing transdermal system to direct external heat sources (eg, hair dryers, heating pads, electric blankets, heated water beds); heat may increase rate and extent of absorption"
            ],
            "specific": [
                {
                    "type": "Serious cardiovascular reactions",
                    "description": [
                        "Sudden death, stroke, hypertension, and myocardial infarction reported in adults with CNS psychiatrics#stimulants",
                        "Serious cardiovascular reactions have occurred at recommended doses",
                        "Sudden death reported in pediatric patients with structural cardiac abnormalities or other serious heart problems taking CNS psychiatrics#stimulants",
                        "Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems",
                        "Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during treatment "
                    ]
                },
                {
                    "type": "Psychiatric adverse reactions",
                    "description": [
                        "CNS psychiatrics#stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorder",
                        "CNS psychiatrics#stimulants may induce mixed/manic episode in patients with bipolar disorder ",
                        "Before initiating, screen for risk factors for developing a manic episode (eg, comorbid or history of depressive symptoms, family history of suicide, bipolar disorder, depression)",
                        "CNS psychiatrics#stimulants, at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without prior history of psychotic illness or mania",
                        "If these symptoms occur, consider discontinuing treatment"
                    ]
                },
                {
                    "type": "Growth suppression",
                    "description": [
                        "CNS psychiatrics#stimulants associated with weight loss and slowing of growth rate in pediatric patients ",
                        "Closely monitor growth (weight and height) in pediatric patients treated with CNS psychiatrics#stimulants",
                        "Consider interrupting treatment in patients who are not growing or gaining height or weight as expected ",
                        "Not approved for use in children aged <6 years"
                    ]
                },
                {
                    "type": "Application site reactions",
                    "description": [
                        "Local skin reactions (eg, pain, pruritus, burning sensation, erythema, discomfort, edema, swelling) have been reported",
                        "Inform patients that increased skin irritation, discomfort or pain may occur if the same application site is used repeatedly",
                        "Instruct patients to select a different application site each day to minimize skin reactions",
                        "Monitor for these reactions while wearing or immediately after removal; symptoms reported to resolve 2-4 hr after application ",
                        "Discontinue treatment if contact sensitization is suspected "
                    ]
                },
                {
                    "type": "Serotonin syndrome",
                    "description": [
                        "Coadministration with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants (TCAs), fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John Wort may cause serotonin syndrome",
                        "Coadministration with CYP2D6 inhibitors may also increase risk by increasing exposure to dextroamphetamine",
                        "If this situation arises, consider use of an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6",
                        "Serotonin syndrome symptoms may include mental status changes (eg, agitation, hallucinations, delirium, and coma), autonomic instability (eg, tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea). ",
                        "Discontinue treatment and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment",
                        "If coadministered with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate dextroamphetamine transdermal with lower doses, monitor for signs and symptoms of serotonin syndrome during drug initiation or titration",
                        "Inform patients of increased risk for serotonin syndrome"
                    ]
                },
                {
                    "type": "Contact sensitization",
                    "description": [
                        "May lead to contact sensitization (allergic contact dermatitis)",
                        "If contact dermatitis is suspected (erythema accompanied by more intense local reaction such as edema, papules, vesicles that does not significantly improve within 48 hr or spreads beyond the application site), discontinue treatment",
                        "Manifestations of systemic sensitization may include a flare-up of previous dermatitis or of prior positive patch-test sites, or generalized skin eruptions in previously unaffected skin",
                        "Patients who develop contact sensitization and require oral amphetamine treatment should be initiated under close medical supervision",
                        "Some patients may be sensitized to amphetamine by exposure to dextroamphetamine and may not be able to take amphetamine in any form "
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "MAOIs",
                        "Contraindicated during and within 14 days following MAOI treatment",
                        "MAOIs slow amphetamine metabolism, increasing amphetamine’s effect on release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis",
                        "Serotonergic drugs",
                        "Initiate with lower doses; monitor for signs and symptoms of serotonin syndrome",
                        "Concomitant use of dextroamphetamine transdermal with serotonergic drugs may increase risk of serotonin syndrome",
                        "CYP2D6 inhibitors",
                        "Initiate with lower doses; monitor for signs and symptoms of serotonin syndrome",
                        "CYP2D6 inhibitors may increase the exposure of dextroamphetamine and increase the risk of serotonin syndrome",
                        "Alkalinizing agents",
                        "Avoid coadministration",
                        "Urinary alkalinizing agents can increase blood levels and potentiate the effects of amphetamine",
                        "Acidifying agents",
                        "Increase dose based on clinical response",
                        "Urinary acidifying agents can lower blood levels and efficacy of amphetamines",
                        "TCAs",
                        "Closely monitor and adjust or use alternant based on clinical response",
                        "Dextroamphetamine may enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in concentrations of dextroamphetamine in the brain; may also potentiate cardiovascular effects"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid increases effects of dextroamphetamine transdermal by decreasing metabolism. Contraindicated. MAOIs slows amphetamine metabolism, increasing amphetamine?s effect on norepinephrine release and other monoamines from adrenergic nerve endings causing signs of hypertensive crisis. Do not administer dextroamphetamine during or within 14 days following MAOI administration."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "linezolid",
            "description": {
                "common": "linezolid increases effects of dextroamphetamine transdermal by decreasing metabolism. Contraindicated. MAOIs slows amphetamine metabolism, increasing amphetamine?s effect on norepinephrine release and other monoamines from adrenergic nerve endings causing signs of hypertensive crisis. Do not administer dextroamphetamine during or within 14 days following MAOI administration."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine increases effects of dextroamphetamine transdermal by decreasing metabolism. Contraindicated. MAOIs slows amphetamine metabolism, increasing amphetamine?s effect on norepinephrine release and other monoamines from adrenergic nerve endings causing signs of hypertensive crisis. Do not administer dextroamphetamine during or within 14 days following MAOI administration."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine increases effects of dextroamphetamine transdermal by decreasing metabolism. Contraindicated. MAOIs slows amphetamine metabolism, increasing amphetamine?s effect on norepinephrine release and other monoamines from adrenergic nerve endings causing signs of hypertensive crisis. Do not administer dextroamphetamine during or within 14 days following MAOI administration."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine increases effects of dextroamphetamine transdermal by decreasing metabolism. Contraindicated. MAOIs slows amphetamine metabolism, increasing amphetamine?s effect on norepinephrine release and other monoamines from adrenergic nerve endings causing signs of hypertensive crisis. Do not administer dextroamphetamine during or within 14 days following MAOI administration."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "potassium citrate",
            "description": {
                "common": "potassium citrate will increase the level or effect of dextroamphetamine transdermal by  Other (see comment). Avoid or Use Alternate Drug. Urinary alkalinizing agents can increase blood levels and potentiate the action of amphetamine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "potassium citrate/citric acid",
            "description": {
                "common": "potassium citrate/citric acid will increase the level or effect of dextroamphetamine transdermal by  Other (see comment). Avoid or Use Alternate Drug. Urinary alkalinizing agents can increase blood levels and potentiate the action of amphetamine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abiraterone",
            "description": {
                "common": "abiraterone will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "almotriptan",
            "description": {
                "common": "almotriptan, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline will increase the level or effect of dextroamphetamine transdermal by  pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine will increase the level or effect of dextroamphetamine transdermal by  pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ascorbic acid",
            "description": {
                "common": "ascorbic acid will decrease the level or effect of dextroamphetamine transdermal by  Other (see comment). Modify Therapy/Monitor Closely. Urinary acidifying agents can lower blood levels and efficacy of amphetamines. Increase dose of dextroamphetamine transdermal based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupropion",
            "description": {
                "common": "bupropion will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buspirone",
            "description": {
                "common": "buspirone, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cinacalcet",
            "description": {
                "common": "cinacalcet will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citric acid/glucono-delta-lactone/magnesium carbonate",
            "description": {
                "common": "citric acid/glucono-delta-lactone/magnesium carbonate will decrease the level or effect of dextroamphetamine transdermal by  Other (see comment). Modify Therapy/Monitor Closely. Urinary acidifying agents can lower blood levels and efficacy of amphetamines. Increase dose of dextroamphetamine transdermal based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine will increase the level or effect of dextroamphetamine transdermal by  pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cocaine topical",
            "description": {
                "common": "cocaine topical will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "cyclobenzaprine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dacomitinib",
            "description": {
                "common": "dacomitinib will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "desipramine will increase the level or effect of dextroamphetamine transdermal by  pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desvenlafaxine",
            "description": {
                "common": "desvenlafaxine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextromethorphan",
            "description": {
                "common": "dextromethorphan, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin will increase the level or effect of dextroamphetamine transdermal by  pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duloxetine",
            "description": {
                "common": "duloxetine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eletriptan",
            "description": {
                "common": "eletriptan, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "frovatriptan",
            "description": {
                "common": "frovatriptan, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "imipramine will increase the level or effect of dextroamphetamine transdermal by  pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "L-tryptophan",
            "description": {
                "common": "L-tryptophan, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "lisdexamfetamine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "lithium, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorcaserin",
            "description": {
                "common": "lorcaserin, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "maprotiline, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meperidine",
            "description": {
                "common": "meperidine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "methamphetamine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "miconazole oral",
            "description": {
                "common": "miconazole oral will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "milnacipran",
            "description": {
                "common": "milnacipran, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirabegron",
            "description": {
                "common": "mirabegron will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "mirtazapine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naratriptan",
            "description": {
                "common": "naratriptan, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "nortriptyline will increase the level or effect of dextroamphetamine transdermal by  pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "paroxetine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "perphenazine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium acid phosphate",
            "description": {
                "common": "potassium acid phosphate will decrease the level or effect of dextroamphetamine transdermal by  Other (see comment). Modify Therapy/Monitor Closely. Urinary acidifying agents can lower blood levels and efficacy of amphetamines. Increase dose of dextroamphetamine transdermal based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "protriptyline will increase the level or effect of dextroamphetamine transdermal by  pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rizatriptan",
            "description": {
                "common": "rizatriptan, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rolapitant",
            "description": {
                "common": "rolapitant will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sumatriptan",
            "description": {
                "common": "sumatriptan, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terbinafine",
            "description": {
                "common": "terbinafine will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "thioridazine will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tramadol",
            "description": {
                "common": "tramadol, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "trimipramine will increase the level or effect of dextroamphetamine transdermal by  pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "venlafaxine, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vilazodone",
            "description": {
                "common": "vilazodone, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "ziprasidone, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zolmitriptan",
            "description": {
                "common": "zolmitriptan, dextroamphetamine transdermal.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Decreased neutrophils",
            "percent": "14"
        },
        {
            "name": "Decreased appetite",
            "percent": "12"
        },
        {
            "name": "Decreased WBCs in pediatric patients",
            "percent": "10"
        },
        {
            "name": "Insomnia",
            "percent": "8"
        },
        {
            "name": "Application site reactions",
            "percent": "8"
        },
        {
            "name": "discomfort",
            "percent": "6"
        },
        {
            "name": "Headache",
            "percent": "4"
        },
        {
            "name": "Vomiting",
            "percent": "4"
        },
        {
            "name": "Abdominal pain",
            "percent": "3"
        },
        {
            "name": "Nausea",
            "percent": "3"
        },
        {
            "name": "Affect liability",
            "percent": "2"
        },
        {
            "name": "Tic",
            "percent": "2"
        },
        {
            "name": "Irritability",
            "percent": "2"
        },
        {
            "name": "Blood pressure increased",
            "percent": "2"
        },
        {
            "name": "Heart rate increased",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Palpitations",
            "percent": null
        },
        {
            "name": "chest pain",
            "percent": null
        },
        {
            "name": "sudden death",
            "percent": null
        },
        {
            "name": "myocardial infarction",
            "percent": null
        },
        {
            "name": "and cardiomyopathy",
            "percent": null
        },
        {
            "name": "isolated reports",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Vision blurred",
            "percent": null
        },
        {
            "name": "diplopia",
            "percent": null
        },
        {
            "name": "difficulties with visual accommodation",
            "percent": null
        },
        {
            "name": "and mydriasis",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        },
        {
            "name": "constipation",
            "percent": null
        },
        {
            "name": "intestinal ischemia",
            "percent": null
        },
        {
            "name": "and other gastrointestinal disturbances",
            "percent": null
        },
        {
            "name": "Hepatobiliary disorders",
            "percent": null
        },
        {
            "name": "Eosinophilic hepatitis",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "hypersensitivity reactions including angioedema and anaphylactic reactions",
            "percent": null
        },
        {
            "name": "and serious skin rashes",
            "percent": null
        },
        {
            "name": "including Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome and toxic epidermal necrolysis",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Rhabdomyolysis",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "overstimulation",
            "percent": null
        },
        {
            "name": "restlessness",
            "percent": null
        },
        {
            "name": "dyskinesia",
            "percent": null
        },
        {
            "name": "tremor",
            "percent": null
        },
        {
            "name": "tics",
            "percent": null
        },
        {
            "name": "and paresthesia",
            "percent": null
        },
        {
            "name": "including formication",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Psychotic episodes at recommended doses",
            "percent": null
        },
        {
            "name": "depression",
            "percent": null
        },
        {
            "name": "logorrhea",
            "percent": null
        },
        {
            "name": "aggression",
            "percent": null
        },
        {
            "name": "anger",
            "percent": null
        },
        {
            "name": "dermatillomania",
            "percent": null
        },
        {
            "name": "bruxism",
            "percent": null
        },
        {
            "name": "dysphoria",
            "percent": null
        },
        {
            "name": "euphoria",
            "percent": null
        },
        {
            "name": "and irritability",
            "percent": null
        },
        {
            "name": "Reproductive system and breast disorders",
            "percent": null
        },
        {
            "name": "Impotence",
            "percent": null
        },
        {
            "name": "changes in libido",
            "percent": null
        },
        {
            "name": "and frequent or prolonged erections",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Raynaud phenomenon",
            "percent": null
        }
    ]
}